{
    "clinical_study": {
        "@rank": "104273", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "TKI alone until rapid progression"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression."
            }
        ], 
        "brief_summary": {
            "textblock": "There have been reports suggesting that continuous administration of epidermal growth factor\n      receptor-tyrosine kinase inhibitors (EGFR-TKIs) is advantageous for patients in which\n      gradual disease progression was observed after the establishment of clinical benefit from\n      EGFR-TKIs. However, whether EGFR TKI with or without chemotherapy provides more survival\n      benefit has not been formally evaluated."
        }, 
        "brief_title": "Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "We design this clinical trial to compare the efficacy of continuation of EGFR TKI with or\n      without chemotherapy in patients beyond gradual progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Patient who was confirmed stage IV NSCLC by pathologic histology or cytology. Males or\n        females aged \u226518 years, < 75 years. Eastern Cooperative Oncology Group (ECOG) performance\n        status 0-2. Life expectancy \u226512 weeks.\n\n        Males and females should be contraceptive during the period of the trial until 8 weeks\n        after the last administration of the drug.\n\n        Definition of gradual progression:\n\n          1. Slow PD (6 months of partial response/stable disease),\n\n          2. Asymptomatic minimal PD,\n\n          3. New brain metastasis controlled locally. Patients with asymptomatic, treated brain\n             metastases are eligible for trial participation.\n\n        Adequate bone marrow, renal, and liver function are required. Able to comply with the\n        required protocol and follow-up procedures, and able to receive oral medications.\n\n        Institutional review board-approved informed consent will be obtained for every patient\n        before initiation of any trial-specific procedure or treatment.\n\n        Exclusion criteria\uff1a Any unstable systemic disease (including active infection,\n        uncontrolled hypertension, unstable angina, congestive heart failure, myocardial\n        infarction within the previous year, serious cardiac arrhythmia requiring medication,\n        hepatic, renal, or metabolic disease).\n\n        Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome,\n        or inability to take oral medication, or have active peptic ulcer disease.\n\n        Female subjects should not be pregnant or breast-feeding. Adequate hematological function:\n        Absolute neutrophil count (ANC) \u22651.5 x 109/L, and Platelet count \u2265100 x 109/L.\n\n        Adequate renal function: Serum creatinine \u2264 1.5 x ULN, or \u2265 50 ml/min. Adequate liver\n        function :Total bilirubin \u00a3 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase\n        (ALT )and Aspartate Aminotransferase (AST )< 2.5 x ULN in the absence of liver metastases,\n        or < 5 x ULN in case of liver metastases.\n\n        Patient assessed by the investigator to be unable or unwilling to comply with the\n        requirements of the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998061", 
            "org_study_id": "ZhejiangU"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Arm A", 
                "intervention_name": "EGFR tyrosine kinase inhibitor", 
                "intervention_type": "Drug", 
                "other_name": "EGFR TKI"
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Arm B", 
                "intervention_name": "EGFR tyrosine kinase inhibitor with chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": "EGFR TKI with chemotherapy"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "doczq.2008@gmail.com", 
                "last_name": "Qiong Zhao, PhD", 
                "phone": "0571-87236802"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310003"
                }, 
                "name": "Qiong Zhao"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC)", 
        "other_outcome": {
            "measure": "Quality of life", 
            "safety_issue": "No", 
            "time_frame": "up to 24 months"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "up to 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998061"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Qiong Zhao", 
            "investigator_title": "Chief of Department of Thoracic Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Objective response rate cacy", 
            "safety_issue": "No", 
            "time_frame": "up to 18 months"
        }, 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}